Twenty percent of patients were alive at 2 years. Xiao W, Chen WW, Sorbara L. Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion. However, RS-like, DLBCL arising from CLL can either be clonally unrelated (21%) or clonally related (79%) to CLL.8 Richter's transformation to clonally unrelated DLBCL is characterized by a significantly lower prevalence of TP53 mutations/deletions and a significantly longer median survival than clonally related DLBCL (62 vs 14 months).8 Most patients with Richter's transformation to clonally related DLBCL carry unmutated IGHV.27 Molecular analysis is useful to establish the clonal relationship between baseline CLL tumor cells and histologically transformed tumor cells (see HT-1, page 14). In a single-institution retrospective cohort study of 46 patients with Richter's transformation treated with R-EPOCH (rituximab/etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin), the ORR was 39% (17 of the 44 patients evaluable for treatment response).29 After a median follow-up of 39 months, median PFS and OS were 4 and 6 months, respectively. Ding W, LaPlant BR, Call TG. It is unclear that the use of alternative anti-CD20 monoclonal antibody poses the same risk of recurrence. Patients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine. The relationship of CTL019 product viability release testing and overall response, progression-free survival, overall survival, sensitivity/specificity of viability testing to predict complete response, and CAR T-cell expansion were examined. (NHODG-E 3 of  4). Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Anderson MA, Tam C, Lew TE. Diarrhea (31%), pyrexia (23%), and fatigue (23%) were the most common treatment-related grade 1/2 adverse events. The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). For 123 ALL pts, median product viability was 89.3% (range: 56.0%-98.4%); 15 pts had products with < 80% viability. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. Version 2.2019 © National Comprehensive Cancer Network, Inc. 2019. Outcome analysis was restricted to patients, de novo or at transformation, who received anthracycline-based chemotherapy. For Second-line and Subsequent Therapy (MZL-A 2 of 3). Kadri S, Lee J, Fitzpatrick C. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. The primary end point was the rate of objective response (calculated as the combined rates of complete response and partial response). Blood 2017;129:3419–3427. 1 Specifically, the updated guidelines now include tafasitamab-cxix in combination with lenalidomide with a category 2A designation as an option for the … FL of any grade that is found to contain an area of DLBCL should be managed as a DLBCL. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). Blood 2011;117:3391–3401. However, some panel members felt that given the unmet clinical need and the lack of effective treatment options, inclusion of PD-1 monoclonal antibodies (nivolumab and pembrolizumab) as a treatment option is reasonable (based on the data discussed earlier) for patients with Richter's transformation refractory to chemoimmunotherapy (especially if considering alloHCT). (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy Acceleration Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216 .). Blood 2014;123:2783–2790. NCCN Guidelines ® recommend acalabrutinib (CALQUENCE) as a second-line therapy option for MCL (Category 2A).. NCCN Guidelines ® B-cell Lymphomas (Version 4.2018–May 15, 2018) 1. Nivolumab and pembrolizumab with or without ibrutinib are reasonable treatment options for patients with del(17p) or TP53 mutation or those with chemotherapy-refractory disease. No association was observed between MYC rearrangement partner and overall survival (HR, 1.00; P=.99). Continuing pharmacy education credit is reported to the CPE Monitor once you have completed the posttest and evaluation and claimed your credits. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature.